Sign in
SuspendedPhase 1

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Key facts

Who runs it
Bellicum Pharmaceuticals
Where
Atlanta, Buffalo, Chicago, Duarte, Hackensack, Houston, and La Jolla, United StatesSee the 7 locations
Trial code
Status
Suspended
Phase
Phase 1
People taking part
220 people, planned
Started
7 Dec 2020
Expected to end
2 Jan 2027
Type of study
Interventional
Treatments tested
  • chimeric antigen receptor (CAR) T cell therapy
Record updated
20 April 2023
Why it stopped
Due to a Dose Limiting Toxicity in another sister trial with same technology.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Documented evidence of HER2 amplification/overexpression by local testing
  • Histologically or cytologically confirmed diagnosis of a locally advanced unresectable or metastatic HER2+ solid tumor malignancy for which standard treatment is no longer effective, does not exist, or subject is ineligible
  • Subjects with a solid tumor malignancy for which HER2-targeted therapy is approved as a standard treatment (e.g., breast, gastric cancers) must have received prior treatment with approved HER2-directed therapy
  • Measurable disease (at least one target lesion) per RECIST v1.1
  • Life expectancy > 12 weeks
  • ECOG 0-1
  • Adequate organ function

Who cannot take part

  • Prior CAR T cell or other genetically-modified T cell therapy
  • Impaired cardiac function or clinically significant cardiac disease
  • Symptomatic intrinsic lung disease or those with extensive tumor involvement of the lungs
  • Severe intercurrent infection
  • Known HIV positivity
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Pregnant or breastfeeding

7 locations in United States

  • Winship Cancer Institute at Emory UniversityAtlanta, United States
  • Roswell Park Cancer InstituteBuffalo, United States
  • University of ChicagoChicago, United States
  • City of Hope National Medical CenterDuarte, United States
  • John Theurer Cancer Center, Hackensack University Medical CenterHackensack, United States

What happens in this trial

What the trial wants to find out

This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.

The group in the trial

  • HER2-targeted dual-switch CAR-T cellsTreatment being tested

    Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.

    Treatment: chimeric antigen receptor (CAR) T cell therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors
Record updated
20 April 2023